Research programme: intranasal therapeutics - West Pharmaceuticals

Drug Profile

Research programme: intranasal therapeutics - West Pharmaceuticals

Alternative Names: Granisetron intranasal - West Pharmaceuticals; Ketoprofen intranasal - West Pharmaceuticals; Morphine-6-glucuronide intranasal - West Pharmaceuticals; NSAID intranasal - West Pharmaceuticals; Zolpidem intranasal - West Pharmaceuticals

Latest Information Update: 04 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator West Pharmaceutical Services
  • Class
  • Mechanism of Action GABA A receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Insomnia; Nausea and vomiting; Pain

Most Recent Events

  • 14 Dec 2004 This programme is available for licensing (http://www.westpharma.com)
  • 14 Dec 2004 Preclinical trials in Emesis in USA (Intranasal)
  • 14 Dec 2004 Preclinical trials in Insomnia in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top